Traws Pharma Delays Phase 2 Influenza Study After UK Regulatory Review; Shares Down Pre-Bell

MT Newswires Live06-15

Traws Pharma (TRAW) said late Friday that it has deferred a planned Phase 2 human influenza challenge study of its experimental drug, tivoxavir marboxil, after receiving a negative review from the UK's health agency.

The company said the regulatory feedback affects the timing of the study but does not end development of its influenza program.

he drug developer said the drug could still have potential for use in a bird flu outbreak or for prevention in high-risk populations.

Following the setback, Traws said it is advancing backup influenza drug candidates designed to maintain the long-lasting antiviral profile of tivoxavir marboxil while addressing potential regulatory concerns.

The company added that it has sufficient cash to fund operations through the first quarter of 2027.

Shares of the company were down over 19% in Monday's premarket activity.

Price: 1.03, Change: -0.25, Percent Change: -19.53

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2643527717?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-15 18:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2643527717","market":"us","top_or_hot":-1,"title":"Traws Pharma Delays Phase 2 Influenza Study After UK Regulatory Review; Shares Down Pre-Bell","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/TRAW\">Traws Pharma</a> (TRAW) said late Friday that it has deferred a planned Phase 2 human influenza challenge study of its experimental drug, tivoxavir marboxil, after receiving a negative review from the UK's health agency.</p><p>The company said the regulatory feedback affects the timing of the study but does not end development of its influenza program.</p><p>he drug developer said the drug could still have potential for use in a bird flu outbreak or for prevention in high-risk populations.</p><p>Following the setback, Traws said it is advancing backup influenza drug candidates designed to maintain the long-lasting antiviral profile of tivoxavir marboxil while addressing potential regulatory concerns.</p><p>The company added that it has sufficient cash to fund operations through the first quarter of 2027.</p><p>Shares of the company were down over 19% in Monday's premarket activity.</p><p>Price: 1.03, Change: -0.25, Percent Change: -19.53</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Traws Pharma Delays Phase 2 Influenza Study After UK Regulatory Review; Shares Down Pre-Bell</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTraws Pharma Delays Phase 2 Influenza Study After UK Regulatory Review; Shares Down Pre-Bell\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-15 18:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/TRAW\">Traws Pharma</a> (TRAW) said late Friday that it has deferred a planned Phase 2 human influenza challenge study of its experimental drug, tivoxavir marboxil, after receiving a negative review from the UK's health agency.</p><p>The company said the regulatory feedback affects the timing of the study but does not end development of its influenza program.</p><p>he drug developer said the drug could still have potential for use in a bird flu outbreak or for prevention in high-risk populations.</p><p>Following the setback, Traws said it is advancing backup influenza drug candidates designed to maintain the long-lasting antiviral profile of tivoxavir marboxil while addressing potential regulatory concerns.</p><p>The company added that it has sufficient cash to fund operations through the first quarter of 2027.</p><p>Shares of the company were down over 19% in Monday's premarket activity.</p><p>Price: 1.03, Change: -0.25, Percent Change: -19.53</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2643527717","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2643527717","pubTimestamp":1781520148,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Traws Pharma (TRAW) said late Friday that it has deferred a planned Phase 2 human influenza challenge study of its experimental drug, tivoxavir marboxil, after receiving a negative review from the UK'","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","TRAW":"TRAWS PHARMA"},"translate_title":"Traws Pharma在英国监管审查后推迟第二阶段流感研究；盘前股价下跌","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TRAW":1},"content_text":"Traws Pharma (TRAW) said late Friday that it has deferred a planned Phase 2 human influenza challenge study of its experimental drug, tivoxavir marboxil, after receiving a negative review from the UK's health agency.The company said the regulatory feedback affects the timing of the study but does not end development of its influenza program.he drug developer said the drug could still have potential for use in a bird flu outbreak or for prevention in high-risk populations.Following the setback, Traws said it is advancing backup influenza drug candidates designed to maintain the long-lasting antiviral profile of tivoxavir marboxil while addressing potential regulatory concerns.The company added that it has sufficient cash to fund operations through the first quarter of 2027.Shares of the company were down over 19% in Monday's premarket activity.Price: 1.03, Change: -0.25, Percent Change: -19.53","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2643527717","isCrawlerRequest":true}